Local supplements to the digestion of health insurance varieties accelerated, and a large number of drugs will withdraw from health insurance.

"Pharmaceutical Network Industry Dynamics" August 3, Anhui Provincial Health Insurance Bureau announced the provincial supplement of Class B drugs in 2020 digestive drugs.
documents show that, in accordance with the State", the original provincial drug catalogue in accordance with the provisions of the addition of Class B drugs, should be gradually digested within 3 years.
" requirements, on the basis of full consideration of the drug habits of the insured people, according to the Anhui Province pharmaceutical centralized procurement platform procurement data, Anhui Provincial Health Insurance Bureau has drawn up a total of 160 drugs to be digested in 2020, a total of 160 drugs will be transferred out of Anhui Province in 2020.
of these, including 58 drugs not purchased in the provincial drug harvesting platform network, the three-year provincial drug harvesting platform procurement volume in 2017-2019 are "0" drugs 87, 2019 procurement volume of "0" drugs 15.
In fact, on August 20 last year, the State Health Insurance Administration officially issued the 2019 edition of the National Health Insurance Directory, and at the same time put forward: "All localities should strictly implement the "Drug Catalog", for the original provincial drug catalog in accordance with the provisions of the increase in Class B drugs, should be gradually digested within 3 years."
the digestion process, the provinces should give priority to the drug included in the scope of national key monitoring to adjust the scope of payment", the local supplement of medical insurance varieties digestion has begun to become more and more intense.
And on February 5 this year, the State Health Insurance Administration issued the "2020 Health Insurance Key Points Notice" referring to the strengthening of the management of the medical insurance catalogue - the establishment of a dynamic adjustment mechanism for the medical insurance drug catalogue, strengthen supervision and dispatch, and promote local progress to complete the digestion of self-replenishing varieties.
, the Department of Pharmaceutical Prices and Tendering and Procurement of the National Health Insurance Administration issued a focus on 2020.
clearly require all regions as soon as possible to develop a three-year digestion plan for additional varieties, by the end of June this year, the national key monitoring varieties out of the catalog, and complete 40% of the provincial added varieties digestion.
for the local supplement of health insurance varieties digested, carried out another speed up, more and more provinces are speeding up the clean-up of local supplement varieties.
According to incomplete statistics, at present, with the support of policies, Jiangxi, Shandong, Beijing, Hunan, Sichuan, Guangdong, Tianjin, Zhejiang, Anhui, Guangxi and other at least 15 provinces and cities on the local health insurance catalog of additional varieties to remove the explicit text, at least 4 provinces and cities to local health insurance supplement varieties to give a specific directory or guidance.
from the above-mentioned provinces to adjust the situation, the provinces have basically achieved the focus of monitoring varieties first step out of health insurance, but the specific size of varieties and the corresponding time nodes relatively there are some differences.
is worth noting that although many provinces transferred products, some are already relatively thin profit margins, abandoned shell products, or even only approved products.
with the increase in the frequency of adjustment of the national health insurance directory, some drugs with high prices, inso-clinical efficacy and obvious therapeutic advantages are also facing the pressure of losing their health insurance reimbursements.
future, under the background of the overall more dynamic adjustment of medical insurance, the relevant pharmaceutical companies must accelerate their approach to the value orientation of medical insurance, pay attention to the clinical safety and effectiveness of drug use, and further improve the cost-effectiveness of their products.
.